Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 14/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.55 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156718 | 1.00 | MAOB (0.61) | MAOBMRGPRX4EGFRERBB2ERBB3 | |
| SCHEMBL29514868 | 1.00 | MAOB (0.61) | MAOBMRGPRX4EGFRERBB2ERBB3 | |
| Hydrochloric Acid SCHEMBL216004 | 0.99 | MAOB (0.62) | MAOBMRGPRX4EGFRERBB2ERBB3 | |
| SCHEMBL12727544 | 0.86 | MAOB (0.48) | MAOBMRGPRX4EGFRERBB2ERBB3 | |
| SCHEMBL6827590 | 0.85 | MRGPRX4 (0.64) | MAOBMRGPRX4IDO1AGXT | |
| SCHEMBL3321494 | 0.85 | MAOB (0.65) | MAOBMRGPRX4IDO1AGXT | |
| SCHEMBL20535609 | 0.84 | MAOB (0.55) | MAOBMRGPRX4EGFRERBB2IDO1 | |
| SCHEMBL22874527 | 0.84 | EGFR (0.55) | MRGPRX4EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL25648997 | 0.84 | EGFR (0.55) | MAOBMRGPRX4EGFRERBB2ERBB3 | |
| SCHEMBL31193398 | 0.83 | MAOB (0.56) | MAOBMRGPRX4IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4673149-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | Trustlife Global Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| CN-119390683-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-118652239-A | Synthesis and application of EGFR allosteric inhibitors | 江南大学 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024179699-A1 | NEW COMPOUNDS AND TREATMENT OF RENAL CELL CARCINOMA | BASH BIOTECH INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-115109036-B | Quinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-115894455-B | Quinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-115073361-B | Rosin diterpenoid compound and preparation method and application thereof | 广东药科大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-115894486-B | Hydrogenated pyridoquinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-115894486-A | Hydrogenated pyridoquinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115894455-A | Quinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-112574177-B | Pyrimidine derivatives and application thereof in preparing antitumor drugs | 陕西师范大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-115109036-A | Quinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-115073361-A | Rosin diterpenoid compound and preparation method and application thereof | 广东药科大学 | 2022-09-20 | — | — | CN | disclosed |
| EP-4013749-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | Black Diamond Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-108484541-B | Synthesis method of 5-formyl furan-2-ethyl nitrobenzoate | 济南大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-110950871-B | 2-substituted-4-arylamino pyrazolotriazine derivative and application thereof in preparing antitumor drugs | 陕西师范大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-108069913-B | Bis (morpholinylalkoxy) quinazoline derivative and application thereof in anti-tumor aspect | 陕西师范大学 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022029795-A1 | An environment friendly process for the preparation of Lapatinib Ditosylate of Formula 1(b) | SUMAR BIOTECH LLP (IN) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | MAOB 2378/4885MRGPRX4 2495/4885EGFR 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.